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Objective: High serum thyrotropin (TSH) levels predict cardiovascular disease (CVD). Recently several single
nucleotide polymorphisms (SNPs) associated with TSH levels have been identified, one of them being the
rs4704397 SNP in the phosphodiesterase 8B (PDE8B) gene. If the relation between thyroid function and CVD is
causal, one could also expect rs4704397 genotypes to predict CVD and possibly health in general.
Methods: DNA was prepared and genotyping performed for rs4704397 in subjects who participated in the fourth
survey of the Tromsø Study in 1994–1995 and who were registered with the endpoints myocardial infarction
(MI), type 2 diabetes (T2DM), cancer, or death, as well as a randomly selected control group. Similarly, geno-
typing was performed in subjects who had participated in clinical trials where serum TSH, free T4 (fT4), and free
T3 (fT3) were measured.
Results: From the Tromsø Study, 8938 subjects without thyroid disease or thyroid medication were successfully
genotyped for rs4704397. Among these, 2098 were registered with MI, 1025 with T2DM, 2748 with cancer, and
3592 had died. The minor homozygote genotype (A:A) had a median serum TSH level that was 0.29 mIU/L
higher than in the major homozygote genotype (G:G). The A:A genotype had a significantly increased risk of MI
as compared to the G:G genotype (1.14 [1.00–1.29], hazard ratio [confidence interval], Cox regression with
adjustment for age, sex, and body mass index). No significant associations were seen with the other endpoints or
CVD risk factors. Furthermore, subjects with the G:G genotype were significantly taller than subjects with the
A:A genotype (mean difference 1.5 cm). In 584 subjects with serum TSH, fT4, and fT3 measurements, the subjects
with the A:A genotype had significantly higher serum TSH and nonsignificantly lower serum fT3 (mean dif-
ference 0.15 pmol/L) levels than subjects with the G:G genotype.
Conclusion: rs4704397 is associated with thyroid function, risk of MI, and body height. However, confirmation
in other cohorts is needed before firm conclusions can be drawn.
Introduction
The thyroid hormones thyroxine (T4) and triiodothy-ronine (T3) are essential for normal metabolic function
and control a wide range of physiological processes. The se-
cretion of T4 and T3 is regulated by thyrotropin (TSH) from
the pituitary and controlled by a negative-feedback loop. In
primary thyroid disease, high serum TSH levels indicate
hypofunction of the thyroid gland, whereas low levels reflect
hyperfunction. The serum TSH level is therefore a sensitive
indicator of thyroid status (1).
It is well known that overt as well as subclinical hypothy-
roidism are associated with cardiovascular disease (CVD) and
increased mortality (2,3), and it has also been demonstrated
that TSH levels, even within the reference range, predict fatal
coronary heart disease (4). In previous studies, we and others
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have found an association between serum TSH within the
reference range and serum lipid levels (5,6), body weight (7,8),
and blood pressure (9). Altered serum TSH level appears to be
an important risk factor for disease in general.
Whether there is a causal relation between moderately el-
evated serum TSH and future disease is uncertain and can
best be answered by properly performed randomized con-
trolled trials (RCTs). Such RCTs would, however, need to
include a large number of subjects followed for a long period
of time, and so it is unlikely to ever be performed. However,
nature has, in a way, already performed its own ‘‘RCT’’ just
waiting to be analyzed. Thus, the free thyroxine (fT4), free
triiodothyroinine (fT3), and TSH levels are, in part, genetically
determined, as demonstrated in several genome wide asso-
ciation studies (GWAS) where single nucleotide polymor-
phisms (SNPs) related to thyroid function have been
identified (10–12). In particular, the rs4704397 SNP in the
phosphodiesterase 8B (PDE8B) gene appears to be one of the
SNPs most strongly associated with the serum TSH level (13–
15), and one copy of the rare A allele confers a mean increase
of 0.13 mIU/L TSH (13) resulting in a difference between the
major and minor homozygote subjects of *0.25 mIU/L TSH.
This SNP has been associated with subclinical hypothyroid-
ism (15), but to our knowledge has not been evaluated with
regard to CVD and other diseases.
In the fourth survey in the Tromsø Study performed in
1994–1995, blood samples for preparation of DNA were col-
lected and analyzed in more than 9000 subjects. The partici-
pants have been monitored with registration of incident
myocardial infarction (MI), type 2 diabetes (T2DM), cancer,
and death, and we therefore had the opportunity to test if this
SNP is related to hard endpoints as well as CVD risk factors.
Furthermore, we analyzed fT4 and fT3 measurements from a
large cohort of subjects also genotyped for rs4704397, and the




The design of the Tromsø Study has been described in de-
tail by Jacobsen et al. (16). In short, the Tromsø Study is a
longitudinal population-based multipurpose study focusing
on lifestyle-related diseases. The study was initiated in 1974,
and has been repeated six times at regular intervals. The
participants are inhabitants of the municipality of Tromsø in
Northern Norway situated at 69N with a current population
of 70,000 inhabitants. In the fourth survey in 1994–1995
(‘‘1994’’ hereafter), all individuals aged 25 years or older were
invited and 2758 subjects participated, providing an atten-
dance rate of 77%.
Measurements in 1994
The participants completed questionnaires on medical
history including thyroid diseases and thyroid medication.
Blood pressure, height, and weight were measured as previ-
ously described in all subjects, and waist and hip circumfer-
ence was determined in a subgroup (9). Nonfasting blood
samples were analyzed consecutively for serum total choles-
terol, triglycerides, and high-density lipoprotein cholesterol
(HDL-cholesterol) in all subjects (5), and serum TSH (9) and
HbA1c (17) were determined in subgroups. DNA was pre-
pared from blood clots stored at the national CONOR (Cohort
of Norway) bio-bank, located at the HUNT/NTNU biobank
in Levanger (18). The SNP rs4704397 was selected due to the
reported strong association with serum TSH levels (13–15).
The genotyping was performed by LGC Genomics (formerly
KBioscience, Hoddesdon, United Kingdom) using the
KBioscience Competitive Allele-Specific PCR genotyping
system (18).
Selection of subjects for genetic studies
The selection of subjects for the genetic studies has been
described in detail previously (18). In short, the subjects were
primarily selected for evaluation of genetic polymorphisms
and hard endpoints for which there are several registers in the
Tromsø Study. Information on cancer and death are available
from national registries. As all of these endpoints were of
potential interest regarding genetic polymorphisms, and
limited funding did not allow genetic analyses of the entire
Tromsø Study cohort, a case-cohort design was used with
randomly selected controls from the entire cohort who at-
tended the fourth survey in 1994 (19). The selection of the
controls was unrelated to the characteristics of the cases ex-
cept for age. Accordingly, genotyping was performed in all
subjects included in the endpoint registers as well as the
randomly selected controls.
Definition of endpoints
The definitions of incident MI and T2DM have previously
been described in detail (18,20,21). Information on cancer in-
cidence and cancer location was retrieved from the Cancer
Registry of Norway. Information on death was obtained from
the Causes of Death Registry, and information on moving out
of the Tromsø area and emigration from Norway was ob-
tained from the Norwegian Registry of Vital Statistics.
Study on subjects with TSH, fT4, and fT3 measurements
In the present study, we pooled baseline data from a vita-
min D and bone-density study including 297 postmenopausal
women aged 50–80 years with a T-score in total hip or lumbar
spine (L2–4) £ - 2.0 (22), and a vitamin D and depression
study comprising 357 subjects aged 30–75 years (23).
Serum TSH, fT4, and fT3 were measured as previously de-
scribed (9).
Statistical analyses
Distribution of the continuous variables was evaluated for
skewness and kurtosis and with visual inspection of histo-
grams, and was found to be normal except for HbA1c and
serum TSH, which were normalized by log transformation
before use as dependent variables. Trends across the SNP
rs4704397 genotypes were evaluated with linear regression
analyses with age, sex, and body mass index (BMI) as cov-
ariates, where appropriate.
The relations between the rs4704397 genotypes with the
endpoints MI, T2DM, cancer, and all-cause mortality were
evaluated using Cox proportional hazard regression model
with age, sex, and BMI as covariates. The observation time for
mortality was set from the survey in 1994 and for the other
endpoints from birth. These latter endpoint groups therefore
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included both prevalent and incident cases. The endpoints
registers were updated throughout 2008 for T2DM and can-
cer, and throughout 2010 for MI and mortality.
The predefined control cohort was used as controls for the
subjects with a specific endpoint (cases). Since this control
cohort was randomly selected from the entire cohort, it also
included a considerable number of subjects with one or more
endpoints. When analyzing a specific endpoint, subjects in the
control cohort with that specific endpoint were moved to the
case group (which only included subjects with that specific
endpoint). Therefore, the size of the control cohort varied
depending on the endpoint in question.
The genotype frequency was evaluated for Hardy–
Weinberg equilibrium with chi-square analysis (24). For the
Tromsø Study cohort, the chi-square value was 6.43 ( p < 0.05);
in the control cohort, it was 4.24 ( p < 0.05), whereas in the
cohort with subjects with TSH, fT4, and fT3 measurements,
the chi-square value was 3.42 ( p > 0.05; v2 = 3.84 with one
degree of freedom corresponds to a two-tailed probability of
0.05).
Baseline characteristics are presented as mean (SD), median
(25th–75th percentiles), or percentage. All tests were two-
sided, and a p-value of <0.05 was considered statistically
significant.
Ethics
The study was approved by the Regional Committee
for Medical and Health Research Ethics (REK Nord, refer-
ence 2010/2913-4). Only participants with valid written
consent were included. The studies were registered at




Cross-sectional part. A total of 9528 subjects were se-
lected for participation in the study, and DNA was success-
fully prepared and analyzed for rs4704397 in 9388 subjects.
Among these, 450 subjects reported use of medication for
thyroid disease and/or previous or current thyroid disease,
leaving 8938 subjects for the present study. Their baseline
characteristics in relation to rs4704397 genotype are shown in
Table 1. There was a significant increase in body height, body
weight, and waist and hip circumferences across the geno-
types, with the major homozygote (G:G) having the highest
values. Thus, subjects with the G:G genotype had a mean
body height 1.5 cm above the A:A genotype subjects. How-
ever, there was no significant relation to BMI or waist–hip
ratio. There was a significant trend for serum TSH across the
genotypes, with the minor homozygote (A:A) genotype hav-
ing a median serum TSH 0.29 mIU/L higher than the major
homozygote genotype (G:G). No significant effects on blood
pressure or serum lipids were observed. The relation between
body height and rs4704397 genotype was seen in both sexes
and all age groups (Table 2).
Relation between rs4704397 genotypes and end-
points. The total number of potential controls was 3932, and
2098, 1025, 2748, and 3592 subjects were registered with MI,
T2DM, cancer, or death respectively. Their characteristics in
1994 are shown in Table 3. In Table 4, hazard ratios for the
endpoints according to genotype are presented with the major
homozygote as reference. The minor homozygote genotype
A:A, which was the one associated with the highest serum
Table 1. Baseline Characteristics of the 8938 Subjects in 1994
in Relation to rs4704397 Genotype: The Tromsø Study
rs4704397 (PDE8B)
A:A A:G G:G
All subjects in the fourth survey of the Tromsø Study
N 1399 4129 3410
Males (%) 46.7 48.5 50.2
Age (years) 59.8 (13.6) 59.2 (13.7) 59.5 (13.8)
Smokers (%) 35.4 35.1 33.9
Systolic blood pressure (mmHg) 144.4 (24.1) 145.0 (24.0) 145.0 (23.5)
Diastolic blood pressure (mmHg) 82.5 (13.1) 83.1 (13.6) 83.1 (13.4)
Body height (cm) 167.1 (9.7) 168.1 (9.8) 168.6 (9.6)***
Body weight (kg) 72.6 (14.0) 73.5 (14.2) 74.1 (14.2)**
BMI (kg/m2) 25.9 (4.0) 25.9 (4.1) 26.0 (4.2)
Serum total cholesterol (mmol/L) 6.65 (1.31) 6.56 (1.31) 6.59 (1.39)
Serum triglycerides (mmol/L) 1.73 (1.19) 1.69 (1.06) 1.69 (1.10)
Serum HDL-cholesterol (mmol/L) 1.52 (0.44) 1.52 (0.43) 1.51 (0.43)
Subjects with TSH measurements (n) 348 976 813
Serum TSH (mIU/L) 1.74 (1.23, 2.65) 1.64 (1.16, 2.34) 1.45 (1.03, 2.12)***
Subjects with HbA1c measurements (n) 710 1964 1646
HbA1c (%) 5.45 (5.2, 5.7) 5.4 (5.2, 5.7) 5.4 (5.2, 5.7)
Subjects with waist and hip measurements (n) 702 1963 1651
Waist (cm) 90.4 (11.5) 91.1 (11.5) 91.8 (11.6)*
Hip (cm) 103.1 (7.9) 103.5 (8.1) 103.9 (7.9)*
Waist–hip ratio 0.88 (0.09) 0.88 (0.08) 0.88 (0.08)
*p < 0.05; **p < 0.01; ***p < 0.001; test of linear trend adjusted for age, BMI (where appropriate) and gender. Data are shown as mean (SD),
median (25th–75th percentiles), or percentage.
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TSH levels, had a significant 14% increased risk for MI. For
the other endpoints, no significant relations to rs4704397
genotypes were seen.
Study on subjects with TSH, fT4, and fT3 measure-
ments. A total of 289 subjects in the osteoporosis study and
341 subjects in the depression study had complete data sets.
Among these subjects, 46 were using thyroid medication or
had thyroid disease and were therefore excluded, thus leaving
584 for the present analysis. The pooled characteristics in re-
lation to rs4704397 genotypes are shown in Table 5. There was
a significant linear trend across the rs4704397 genotypes for
serum TSH with the minor homozygote A:A having the
highest serum TSH levels. There was a trend for a reciprocal
association with fT3, with the genotype A:A having the lowest
level. However, this was not statistically significant after in-
clusion of BMI in the analysis.
Discussion
In the present study, we have confirmed the relation be-
tween rs4704397 genotypes and serum TSH, and also dem-
onstrated a possible relation to fT3. Furthermore, there was a
significant relation between rs4704397 genotypes and body
height and risk of MI, but not for the other endpoints—T2DM,
cancer, or mortality.
Table 2. Body Height in 1994 in Relation to Gender, Age, and rs4704397 Genotype: The Tromsø Study
rs4704397 (PDE8B)
A:A A:G G:G
n Height (cm) n Height (cm) n Height (cm)
Males
All males 653 174.5 (7.0) 2002 175.2 (7.2) 1711 175.6 (6.9)**
Age < 50 years 161 176.9 (6.7) 520 177.5 (7.2) 447 178.3 (6.7)*
Age 50–69 years 346 174.6 (6.8) 1041 175.1 (7.0) 860 175.7 (6.3)**
Age > 69 years 146 171.7 (6.9) 441 172.6 (6.6) 404 172.4 (7.1)
Females
All females 746 160.7 (6.7) 2127 161.5 (6.9) 1699 161.6 (6.3)*
Age < 50 years 176 163.5 (6.5) 556 165.4 (6.5) 417 165.4 (5.6)**
Age 50–69 years 359 161.4 (6.0) 962 161.6 (6.2) 784 161.7 (5.7)
Age > 69 years 211 157.0 (6.5) 609 157.7 (6.3) 498 158.4 (6.0)**
*p < 0.05; **p < 0.01; test of linear trend.
Table 3. Baseline Characteristics in 1994 of the Subjects in the Control Group,
and Subjects with MI, T2DM, Cancer, and Death: The Tromsø Study
Control group MI T2DM Cancer Death
N 3932 2098 1025 2748 3592
Males (%) 44.5 65.7 53.7 49.9 53.5
Age (years) 65.5 (12.6) 64.2 (12.0) 59.9 (12.5) 58.9 (13.8) 67.1 (12.7)
Smokers (%) 27.6 36.0 29.5 36.7 35.7
Systolic blood pressure
(mmHg)
149.0 (24.7) 151.1 (24.1) 151.7 (23.3) 142.8 (23.3) 152.2 (25.4)
Diastolic blood pressure
(mmHg)
83.8 (13.8) 86.0 (13.8) 86.3 (13.7) 81.9 (13.1) 85.2 (14.5)
BMI (kg/m2) 25.9 (4.1) 26.6 (4.0) 29.0 (4.8) 25.7 (4.0) 25.9 (4.3)
Serum total cholesterol
(mmol/L)
6.69 (1.33) 6.93 (1.28) 6.69 (1.22) 6.41 (1.31) 6.69 (1.34)
Serum triglycerides
(mmol/L)
1,68 (1.07) 1.98 (1.22) 2.40 (1.57) 1.61 (1.01) 1.75 (1.09)
Serum HDL-cholesterol
(mmol/L)
1.54 (0.44) 1.39 (0.40) 1.32 (0.38) 1.52 (0.42) 1.51 (0.44)
Subjects with TSH
measurements (n)
1005 557 278 642 847
Serum TSH (mIU/L) 1.61 (1.14, 2.34) 1.53 (1.10, 2.28) 1.59 (1.17, 2.16) 1.61 (1.13, 2.23) 1.58 (1.07, 2.25)
Subjects with HbA1c
measurements (n)
1967 1096 527 1319 1662
HbA1c (%) 5.4 (5.2, 5.7) 5.5 (5.2, 5.8) 5.9 (5.6, 6.6) 5.4 (5.2, 5.7) 5.5 (5.2, 5.7)
Subjects with waist/hip
measurements (n)
2027 1153 543 1291 1739
Waist–hip ratio 0.87 (0.81, 0.93) 0.91(0.85, 0.96) 0.92 (0.86, 0.97) 0.88 (0.82, 0.93) 0.89 (0.83, 0.95)
Data are shown as mean (SD), median (25th–75th percentiles), or percentage.
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The relation between rs4704397 and serum TSH has been
reported before. Arnaud-Lopez et al. genotyped 362,129 SNPs
in 4300 subjects and found a strong relation between
rs4704397 and serum TSH, a finding that was replicated in
another 4158 subjects (13). Each copy of the minor allele was
associated with an increase of 0.13 lIU/mL in serum TSH,
which is comparable to what we found in our two cohorts.
This was confirmed in a study by Shields et al. in 877 pregnant
women (15), and also in a meta-analysis by Taylor et al. who,
in addition to the relation with serum TSH, also found a
reciprocal association with fT4, indicating relative hypo-
thyroidism (14). In our study, we found a corresponding
reciprocal association with fT3, which could indicate rela-
tive hypothyroidism. However, the association was weak and
not significant after inclusion of BMI in the analysis. Similarly,
in the two large studies by Gudmundsson et al. (11) and by
Porcu et al. (12), this reciprocal relation was not statistically
significant.
The mechanism for this effect, if present, is most likely due
to the function of the PDE8B gene, where the SNP rs4704397 is
located, as it encodes a high-affinity cAMP-specific phos-
phodiesterase (25). The PDE8B gene is not expressed in the
pituitary (26) but in the thyroid where it is supposed to cat-
alyze inactivation of cAMP after TSH stimulation (13). Thus,
as thyroid hormone secretion is stimulated by TSH via a
cAMP-dependent pathway (27), the PDE8B gene could in-
fluence the TSH level by affecting the T4 and T3 secretion by
the thyroid (13).
Thyroid function affects longitudinal bone growth, and
hypothyroidism is associated with retarded growth (28). For
subclinical hypothyroidism, there are only a few studies in
children/adolescents, and it appears that thyroxine treatment
leads to increased growth (29). Our finding of a relation be-
tween rs4704397 SNP and body height is therefore plausible.
It would have been of great interest to see if this relation also
applied to children and adolescents, but unfortunately we did
not have any subjects younger than 25 years of age. The mean
difference in height between the major and minor homozy-
gote genotypes for the rs4704397 SNP was 1.5 cm. This is a
considerable height difference, as according to most analyses,
the effect size of SNPs associated with height ranges from 0.2
to 0.5 cm per allele (30). More than 200 polymorphisms asso-
ciated with adult height have been identified (30,31). Even
when all these SNPs are taken together, they can only explain
45% of the genetic variance in height (32). It is probable that a
number of SNPs have not been ‘‘detected’’ by GWAS, since
SNPs with minor effects will not pass the stringent signifi-
cance tests in these studies. In our study, we used a different
approach and only included one SNP based on the known
relation to serum TSH and thereby avoided the need for
correcting for testing a multitude of SNPs.
In addition to elucidating factors that determine adult
height, our finding may shed light on other diseases. In this
regard, it is noteworthy that body height has been associated
with several cancers (33), CVD (34), as well as mortality (35).
However, the most remarkable finding in our study was the
relation between rs4704397 and the risk of MI. It is well
known that overt hypothyroidism is associated with athero-
sclerosis and heart disease (2), which also seems to be the case
for subclinical hypothyroidism. Thus, in the meta-analysis by
Table 4. Number of Subjects with Specific Endpoints and Number of Subjects in Corresponding Control
Groups and Hazard Ratio with Confidence Interval in Relation to Genotype: The Tromsø Study
MI T2DM Cancer Death
Endpoint (n) 2098 1025 2748 3592
Controls (n) 3078 3600 3075 2244
rs4704397
Major homozygote (G:G) Reference Reference Reference Reference
Heterozygote (G:A) 1.07 (0.97–1.17) 1.06 (0.92–1.21) 1.02 (0.94–1.11) 1.00 (0.93–1.08)
Minor homozygote (A:A) 1.14 (1.00–1.29)* 1.02 (0.85–1.24) 1.10 (0.98–1.23) 1.07 (0.97–1.18)
*p < 0.05; Cox regression with adjustment for age, gender, and BMI.
Table 5. Characteristics of the 584 Subjects with Serum TSH, fT4
and fT3 Measurements in Relation to rs4704397 Genotype
rs4704397 (PDE8B)
A:A A:G G:G
All 584 subjects (n) 101 250 233
Osteoporosis study (females only, n) 46 118 94
Depression study (n) 55 132 139
Percentage males in depression study 38.2 46.2 51.1
All 584 subjects
Age (years) 56.5 (11.6) 57.2 (10.0) 56.9 (10.2)
BMI (kg/m2) 26.4 (4.2) 26.2 (4.0) 26.3 (3.8)
Serum TSH (mIU/L)* 1.89 (1.30, 2.46) 1.58 (1.17, 2.24) 1.63 (1.12, 2.13) **
Serum FT4 (nmol/L) 15.7 (2.1) 15.9 (2.0) 16.1 (2.2)
Serum FT3 (pmol/L) 4.57 (0.56) 4.63 (0.62) 4.72 (0.60)
*Log transformed in the linear regression. **p < 0.05; test of linear trend adjusted for age, BMI, and gender. Data are shown as mean (SD),
median (25th–75th percentiles), or percentage.
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Rodondi et al., subclinical hypothyroidism (defined as ele-
vated serum TSH with normal fT4) was associated with in-
creased risk of coronary heart disease (3). Of note was that the
results were similar after further adjustment for traditional
cardiovascular risk factors like blood pressure and choles-
terol, and that they did not differ by age or sex. The relation
between TSH and coronary disease has even been demon-
strated within the serum TSH reference range in the HUNT
study, a large population-based cohort study from Norway
(4). The study included 17,311 women and 8002 men without
known thyroid or cardiovascular disease or diabetes mellitus
at baseline followed up for a median of 8.3 years. Among the
subjects with TSH within the reference range at baseline (0.50–
3.5 mIU/L), the TSH levels were positively associated with
mortality from coronary heart disease, the trend being sta-
tistically significant in women but not in men (4). This finding
was later confirmed from the same group after a median
follow-up time of 12.3 years (36).
Accordingly, small changes in TSH may have considerable
effects on CVD. However, cross-sectional or prospective
studies cannot answer the question of causality, for which
RCTs are needed. A surrogate for RCT is to use the Mendelian
randomization approach (37) where the cohort at birth (or
conception) is considered ‘‘randomized’’ to a certain geno-
type. In the case of rs4704397, individuals ‘‘randomized’’ to
the minor homozygote genotype will presumably have higher
TSH levels and possibly also lower fT3 levels throughout life
than the individuals ‘‘randomized’’ to the major homozygote
genotype. Accordingly, this difference in thyroid function,
although small, will be present throughout life and may
therefore be a stronger predictor of health than a single TSH
measurement, as is usually the case in prospective studies.
Our finding of a relation between rs4704397 and the risk of MI
is therefore not unexpected. Similar to that seen for subclinical
hypothyroidism, the relation can hardly be explained by as-
sociation with the classical risk factors for atherosclerosis such
as blood pressure and hyperlipidemia, as there was no asso-
ciation with these risk factors and rs4704397. Furthermore, it
was not related to BMI, which was included in the analyses
because an interaction between adiposity and the PDE8B gene
on serum TSH has been described (38). On the other hand, it
could possibly be related to other factors like increased sys-
temic vascular resistance, arterial stiffness, altered endothelial
function, and coagulability, which have all been reported to
be associated with subclinical hypothyroidism and which
may accelerate development of coronary heart disease (39).
Although the result from the Mendelian randomization
was significant, this is still not proof of a causal relation. Thus,
the rs4704397 SNP could very well be associated with other
genes that were the ones truly causing the observed effect, and
therefore rs4704397 may only be a marker of disease risk.
Furthermore, the Tromsø Study population was not in Hardy–
Weinberg equilibrium regarding rs4704397, and the results
may therefore have been biased. This could possibly be ex-
plained by the high proportion of Sami ancestry in the Tromsø
population (40), as this group could have a different allele
frequency than the majority of the Tromsø population, which is
a non-Sami Caucasian population. Unfortunately, we did not
have any ancestry-informative SNPs that could verify this
hypothesis. However, in the control group, the deviation from
the Hardy–Weinberg equilibrium was small, and the results
can therefore most likely be considered reliable.
In conclusion, we have found rs4704397 to be associated
with the serum TSH and fT3 levels with a corresponding in-
creased risk of MI. This is an argument for, but no proof of, a
causal relation between increased TSH levels and cardiovas-
cular risk. Furthermore, as is the case with all genetic studies
of this type, confirmation in other cohorts is needed.
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